Abstract
After the discovery of prostacyclin (PGI2) in 1976 [1], the most potent inhibitor of human platelet aggregation in vitro [1] with simultaneous strong hypotensive effect in animals and humans [1, 2, 3], many efforts have been made to synthesize PGI2-derivatives that are chemically stable and which possibly have longer lasting action. The first goal has been reached easily enough and carboprostacyclin [4, 5], 10,10-difluoro-13,14-dehydroprostacyclin [6] and 16-methyl-18 yl carboprostacyclin (ZK-36374) [7] are the best known results of these efforts.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
S. Moncada, R. J. Gryglewski, S. Bunting, and J. R. Vane, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature, 263: 663 (1976).
R. J. Gryglewski, S. Bunting, S. Moncada, R. J. Flower, and J. R. Vane, Arterial walls are protected against deposition of platelet thrombi by a substances (Prostaglandin X) which they make from prostaglandin endoperoxides, Prostaglandins, 12: 685 (1976).
A. Szczeklik, R. J. Gryglewski, R. Nizankowski, J. Musial, R. Pieton, and J. Mruk, Circulatory and antiplatelet effects of intravenous prostacyclin in healthy man, Pharm. Res. Commun., 10: 545 (1978).
B. J. R. Whittle, S. Moncada, F. Whiting, and J. R. Vane, Carbacyclin - a potent prostacyclin analog for the inhibition of platelet aggregation, Prostaglandins, 19: 605 (1980).
R. Ceserani, M. Grossoni, D. Longiave, B. Mizzotti, 0. Pozzi, A. Dembinska-Kiec’, and S. Bianco, dl-9a-deoxy-9a-methylenePGI2 (a stable prostacyclin derivative): preliminary pharmacological data, Prostaglandins and Medicine, 5: 131 (1980).
Y. Hatano, J. Kohli, L. I. Goldberg, J. Fried, and M. M. Mehrotra, Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin, Proc. Natl. Acad. Sci., USA, 77: 6846 (1980).
K. Schrdr, H. Darius, R. Matzky, and R. Ohlendorf, The anti-platelet and cardiovascular actions of a new carbacyclin derivative (ZK 36374) equipotent to PGI2 in vitro, Naunyn-Schmiedeberg’s Arch. Pharmacol., 316: 252 (1981).
R. Ceserani, D. Longiave, M. Grossoni, M. Bergamaschi, C. Gondolfi, N. Mongelli, and L. Zuliani, 5E-13,14-didehydrocarboprostacyclin and 5E-13,14-didehydro-20-methyl-carboprostacyclin: preliminary data on inhibition of platelet aggregation and hypotensive effect, IRCS Medical Sciences, 9: 364 (1981).
D. J. Finney, Statistical Methods in Biological Assay (C. Griffin, ed. ), London (1972).
H. Grimm, Principles of statistical estimation, in: “Biostatistics in Pharmacology,” Vol. 2 (A. L. Delaunois, ed.), Pergamon Press, Ltd., Oxford, p. 611 (1973).
B. J. R. Baley, Tables of the Bonferroni “t” statistic, J.A.S.A. Vol. 72, No. 358, p. 469 (1977).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Plenum Press, New York
About this chapter
Cite this chapter
Ceserani, R., Grossoni, M., Bergamaschi, M., Zuliani, L., Mongelli, N., Pareti, F.I. (1983). Inhibition of Platelet Aggregation and Cardiovascular Effect of 5E-13,14-Didehydro Carboprostacyclin and 5E-13,14-Didehydro-20-Methyl-Carboprostacyclin. In: Berti, F., Folco, G., Velo, G.P. (eds) Leukotrienes and Prostacyclin. NATO Advanced Science Institutes Series, vol 54. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4391-2_15
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4391-2_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4393-6
Online ISBN: 978-1-4684-4391-2
eBook Packages: Springer Book Archive